Ptc Therapeutics, Inc. · NASDAQ:PTCT

Boulding Mark Elliott sold 5,079 Ptc Therapeutics, Inc. shares (Form 4)

Traded Jul 6, 2026 · Filed Jul 8, 2026

On Jul 6, 2026, Boulding Mark Elliott (EXEC. VP AND CLO) sold 5,079 Ptc Therapeutics, Inc. shares at an average US$85.08 for US$432K under a trading plan, leaving 105,272 shares. Filed Jul 8, 2026 (Form 4).

Sold
5,079 shares
Price
US$85.08 average (US$83.10 to US$86.38)
Value
US$432K
Holding after
105,272 shares
Trading plan
Yes (Made under a plan set in advance)
Role
EXEC. VP AND CLO

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Jul 6, 2026Common StockOption exercise2,266US$39.42107,538Direct
Jul 6, 2026Common StockSale313US$83.10107,225Direct
Jul 6, 2026Common StockSale833US$84.41106,392Direct
Jul 6, 2026Common StockSale519US$85.84105,873Direct
Jul 6, 2026Common StockSale601US$86.38105,272Direct
Jul 6, 2026Common StockOption exercise2,813US$46.54108,085Direct
Jul 6, 2026Common StockSale387US$83.10107,698Direct
Jul 6, 2026Common StockSale1,036US$84.41106,662Direct
Jul 6, 2026Common StockSale645US$85.84106,017Direct
Jul 6, 2026Common StockSale745US$86.38105,272Direct

Source

View original at SEC

Related